Company Overview and News

16
CYBG and Virgin Money agree $2.26 billion deal to create Britain's sixth biggest bank

40m theedgemarkets
LONDON (June 18): Mid-sized bank CYBG has agreed a 1.7 billion pound ($2.26 billion) all-share deal to acquire Virgin Money, which it said will create Britain’s sixth-largest bank and a new challenger to the country’s top four lenders.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

19
PRESS DIGEST- British Business - June 15

2018-06-15 reuters
June 15 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
LLOY TWX STOB LYG TWC LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LNSTY LLD7 LLPC LLD6 LLD1 LLD2

20
U.K. stocks slide as tensions flare-up before the G-7 meets - MarketWatch

2018-06-08 marketwatch
U.K.’s blue-chip stocks slumped Friday in a broader selloff across European equities, with investors preparing for what’s likely to be a tense gathering of leaders in the Group of Seven advanced economies in Quebec.
BT.A HRGLY LLOY BTGOF LYG BT HL LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG HRGLF LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

20
Lloyds Sells Entire Standard Life Aberdeen Stake Amid Tussle - Bloomberg

2018-06-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SLFPF LLOY SL LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2 SLFPY

60
UPDATE 1-UK Stocks-Factors to watch on June 8

2018-06-08 reuters
June 8 (Reuters) - Britain’s FTSE 100 index is seen opening 24 points lower at 7,680 on Friday, according to financial bookmakers, with futures up 0.67 percent ahead of the cash market open.
BP ENB LLOBF EBBNF BT.A ENBBF LLOY BTGOF LYG BP.A BP.B BT ENB LLPH LLPK BP LLPJ LLPE LLPD LLPG LLDTF LLD5 LLD7 LLPC BPAQF LLD6 LLD1 LLD2

16
PRESS DIGEST- Financial Times - June 8

2018-06-07 reuters
June 8 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

16
Lloyds Banking Group A Conviction Buy

2018-06-07 seekingalpha
Lloyds Banking Group PLC (LYG) is in my view the strongest bank in the UK and maybe the whole of Europe.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

16
I Like This Stock

2018-06-06 seekingalpha
I like this stock. I've been in and out of it a few times over the last 10 years. I made a profit each time.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

16
UPDATE 2-Britain takes $2.68 billion loss on RBS share sale

2018-06-05 reuters
LONDON (Reuters) - Britain has sold some of its holding in Royal Bank of Scotland (RBS.L), the bank which it rescued in the 2008 financial crisis, but has taken a loss of more than 2 billion pounds ($2.68 billion) on the deal.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

16
Investor revolt at Circassia over executive pay

2018-05-30 telegraph.co.uk
Pharmaceutical company Circassia suffered a shareholder rebellion at its annual general meeting today after a fifth of investors who voted opposed its remuneration report.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

97
Barclays Gets Fund-Raising Charge Clearance From UK Court

2018-05-22 zacks
The U.K’s Crown Court dismissed all the charges brought by the Serious Fraud Office (SFO) against Barclays PLC (BCS - Free Report) , relating to its series of fund raisings from Qatar Holding LLC in 2008. Details of the Fund Raising Back in 2008, during the peak of the financial crisis, Barclays made a series of funding agreements with Qatar Holding. The company raised nearly £12 billion through the sale of its shares to Qatar Holding, particularly in June and October.
HAFC BCS.PRD BCS DB BCS.PRC BCS.PRA DGLD CS RBS 83SF UGLD 83SK LLOBF RBS AAP AKAM 47MC DSLV LLOY VIIX CSSLF VIIZ LYG LLPH CSGKF BCS.PR LLPK LLPJ LLPE LLPD LLPG LLDTF LLD5 ZIV USLV LLD7 LLPC LLD6 TVIX LLD1 LLD2 XIV

50
Why Barclays Mortgage Deal is Not a Sign to Enter Ireland

2018-05-21 zacks
Last week, Barclays (BCS - Free Report) acquired £4.3 billion ($5.8 billion) worth of Irish residential mortgage loans from Lloyds Banking Group (LYG - Free Report) . The portfolio comprises around 27,000 mortgages, originated between 2004 and 2010. Of the total loans acquired, nearly £300 million are impaired. Mortgage loan portfolio incurred a pre-tax loss of roughly £40 million in 2017. Notably, Lloyds is expected to record £110 million in pre-tax loss on the deal in second-quarter 2018.
WFCNP WFC.PRL WFC.PRJ PRU WFC.PRT WFC.PRR PUK.PRA WFC.PRQ WFC.PRP LLOBF WFC.PRO PUK WFC.PRN 8306 WFC.PRY WFC.PRX MBFJF WFC.PRW CSIQ WFC.PRV PUKPF WFC WFC.WS LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLPG PUK.PR MUFG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 MTU LLD2

128
Deals of the day-Mergers and acquisitions

2018-05-18 reuters
May 18 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Friday:
GSAT C6L CQP PBBGF T8B PYPL SINGY ENB FUJIF 4901 500470 KR LLOBF VIAB EBBNF CBS VIA ENBBF LLOY CBS.A LNG LYG CBS.WD XRX ENB LLPH LLPK LLPJ TTST LLPE LLPD TATASTEEL TATLY LLPG LLDTF LLD5 LLD7 LLPC LLD6 CPV LLD1 FUJIY SINGF LLD2

55
UPDATE 1-UK Stocks-Factors to watch on May 18

2018-05-18 reuters
* JUST GROUP: Private equity investor Permira said on Friday it had sold its entire stake in British specialist pensions provider Just Group for 143 pence a share.
DNLM BP SANT JSNSF LLOBF SAN DNLMY OPHR LLOY HIK JSAIY LYG BP.A BP.B BNC LLPH LLPK BP LLPJ LLPE LLPD LLPG LLDTF LLD5 LLD7 LLPC BPAQF LLD6 LLD1 LLD2

30
Deutsche Bank (DB) CEO Assures Asian Employees of No Exit

2018-05-15 zacks
In a conference held in Singapore, Deutsche Bank’s (DB - Free Report) CEO assured employees in the Asian region that the company intends to continue developing operations in the continent with no plans of exit. The news was reported by Bloomberg.
DB LLOY NTB BMO LYG BMO LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...